Navigation Links
STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
Date:8/26/2009

up share 11 19.6 10.6 3 19.7 EBITDA 12 37.5 20.2 56 - Capital expenditure 93 (21.6) (11.7) 130 - Free cash flow 45 4.9 2.6 (66) - Net financial debts (131) 9.5 (818) - Equity 23 109.0 17 - EPS, diluted 11 1.47 EUR 3 1.48 EUR Dividend rate -1017% 34% 8 34% Dividend per share - 0.50 EUR 11 0.50 EUR

Sales growth and financial position

In spite of the unfavourable economic background, sales were maintained at a high level (up 12% - 11% organic, excluding foreign exchange effect), due to the continuing growth of sublingual treatments. The launch of ORALAIR(R), which started at the end of 2008 in Germany, has confirmed its commercial success.

Selling, general and administrative expenses posted a moderate 8% increase, substantially offset by the growth in sales. The 29% increase in net R&D costs highlighted the continued dynamic development of allergen tablets. In this context, operating profit grew by 7% to EUR 19.6 million. Due to good control of financial expenses, net profit increased by 11% to EUR 13.4 million. Diluted earnings per share amounted to EUR 1.01.

EBITDA grew by 12% to EUR 24.1 million. Against a background of sustained investments, free cash flow rose by 45% to a positive EUR 14.5 million, particularly due to a reduction in working capital requirements. For the first time in 10 years, the net financial position was a positive EUR 1.3 million.

The half-year financial report can be downloaded from the corporate website: http://www.stallergen
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
2. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
3. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
4. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
5. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
6. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
7. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
8. STALLERGENES: 2008: Strong Performance
9. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
10. BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
11. Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... today announced that it has secured $38 million in ... in 2004, the company has raised $92 million in ... round, which consists of two tranches, was led by ... rata participation of existing investors Apax Partners, Clarus Ventures, ...
... April 7 , - ... Ansell Global Healthcare Educational Program, Accepted,for Accreditation , ... leader in healthcare barrier,protective solutions, has announced it has ... community in the area of continued,education. , ...
... Geographical Society,s awards ceremony on Wednesday, April 15, at ... polar explorers - of this planet and of Mars. ... the gargantuan task of relocating the society,s library, described ... the western hemisphere," from New York to Wisconsin in ...
Cached Biology Technology:Aerovance Secures $38 Million in Equity Financing 2Aerovance Secures $38 Million in Equity Financing 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4American Geographical Society awards honor Henson, Smith on April 15 at UD 2American Geographical Society awards honor Henson, Smith on April 15 at UD 3American Geographical Society awards honor Henson, Smith on April 15 at UD 4
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global leader ... series of digital telemetry implants to meet the ... part of the PhysioTel™ Digital platform, was designed ... data when incorporating functional endpoints into repeat-dose toxicology ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE San Diego ... provides the connective tissue that enhances care coordination among social ... client-level information; earned a second $1 million grant from the ... in community and; will be recognized as a "Live Well ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... a group of human subjects to operate a robot-controlled joystick, ... "learns" to control certain muscle movements, the more likely it ... results, the investigators say, could alter rehabilitation approaches for people ... , In a report on the work in the ...
... and exercise performance measures of trained cyclists at high ... a lot -- up to 45% -- while others ... level. , Ten cyclists who took sildenafil at altitude ... kilometers by 15% compared to placebo trials at altitude. ...
... for breast cancer do not increase their life expectancy ... analysis by researchers from UC Davis, UCSF, the University ... addition, the researchers showed that tamoxifen is an extraordinarily ... per year of life saved. The study will be ...
Cached Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3Viagra improves high altitude exercise performance up to 45% for some 2Viagra improves high altitude exercise performance up to 45% for some 3Viagra improves high altitude exercise performance up to 45% for some 4Tamoxifen for breast cancer prevention does not benefit most women 2Tamoxifen for breast cancer prevention does not benefit most women 3
Mouse monoclonal antibody to PPP2R2C - protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Biology Products: